New voice valve could cut down on annoying replacements for throat cancer survivors
NCT ID NCT07369050
First seen Jan 27, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This study tests whether using the Provox ActiValve voice prosthesis as a first choice can reduce the number of times the device needs to be replaced each year in people who have had their voice box removed (laryngectomy) and have a tracheoesophageal puncture (TEP). The trial will enroll 48 adults who are at least 6 months past cancer treatment and have no signs of cancer. Researchers will compare the ActiValve to standard voice prostheses to see if it leads to fewer replacements and fewer complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77090, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Provox® ActiValve® voice prosthesis device
What this could lead to
If it works, this could mean fewer device replacements and less hassle for people who have had a laryngectomy.
What could go wrong
This is a small, early-stage trial with only 48 participants, so results may not apply to everyone. The device may not reduce replacements for all users.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.